A vaccine using Anaplasma marginale subdominant type IV secretion system recombinant proteins was not protective against a virulent challenge
Anaplasma marginale is the most prevalent tick-borne livestock pathogen with worldwide distribution. Bovine anaplasmosis is a significant threat to cattle industry. Anaplasmosis outbreaks in endemic areas are prevented via vaccination with live A. centrale produced in splenectomized calves. Since A. centrale live vaccine can carry other pathogens and cause disease in adult cattle, research efforts are directed to develop safe recombinant subunit vaccines. Previous work found that the subdominant proteins of A. marginale type IV secretion system (T4SS) and the subdominant elongation factor-Tu (Ef-Tu) were involved in the protective immunity against the experimental challenge in cattle immunized with the A. marginale outer membrane (OM). This study evaluated the immunogenicity and protection conferred by recombinant VirB9.1, VirB9.2, VirB10, VirB11, and Ef-Tu proteins cloned and expressed in E. coli. Twenty steers were randomly clustered into four groups (G) of five animals each. Cattle from G1 and G2 were immunized with a mixture of 50 μg of each recombinant protein with Quil A® or Montanide™ adjuvants, respectively. Cattle from G3 and G4 (controls) were immunized with Quil A and Montanide adjuvants, respectively. Cattle received four immunizations at three-week intervals and were challenged with 107 A. marginale-parasitized erythrocytes 42 days after the fourth immunization. After challenge, all cattle showed clinical signs, with a significant drop of packed cell volume and a significant increase of parasitized erythrocytes (p<0.05), requiring treatment with oxytetracycline to prevent death. The levels of IgG2 induced in the immunized groups did not correlate with the observed lack of protection. Additional strategies are required to evaluate the role of these proteins and their potential utility in the development of effective vaccines.
Main Authors: | , , , , , , |
---|---|
Format: | info:ar-repo/semantics/artículo biblioteca |
Language: | eng |
Published: |
PLOS; National Center for Biotechnology Information
2020-02
|
Subjects: | Anaplasma Marginale, Vacuna, Proteínas Recombinantes, Virulencia, Vaccines, Recombinant Proteins, Virulence, |
Online Access: | http://hdl.handle.net/20.500.12123/6996 https://pubmed.ncbi.nlm.nih.gov/32084216/ https://doi.org/10.1371/journal.pone.0229301 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
oai:localhost:20.500.12123-6996 |
---|---|
record_format |
koha |
spelling |
oai:localhost:20.500.12123-69962020-03-27T14:16:52Z A vaccine using Anaplasma marginale subdominant type IV secretion system recombinant proteins was not protective against a virulent challenge Sarli, Macarena Novoa, María Belen Mazzucco, Matilde N. Signorini, Marcelo Echaide, Ignacio Eduardo Echaide, Susana T. de Primo, María Evangelina Anaplasma Marginale Vacuna Proteínas Recombinantes Virulencia Vaccines Recombinant Proteins Virulence Anaplasma marginale is the most prevalent tick-borne livestock pathogen with worldwide distribution. Bovine anaplasmosis is a significant threat to cattle industry. Anaplasmosis outbreaks in endemic areas are prevented via vaccination with live A. centrale produced in splenectomized calves. Since A. centrale live vaccine can carry other pathogens and cause disease in adult cattle, research efforts are directed to develop safe recombinant subunit vaccines. Previous work found that the subdominant proteins of A. marginale type IV secretion system (T4SS) and the subdominant elongation factor-Tu (Ef-Tu) were involved in the protective immunity against the experimental challenge in cattle immunized with the A. marginale outer membrane (OM). This study evaluated the immunogenicity and protection conferred by recombinant VirB9.1, VirB9.2, VirB10, VirB11, and Ef-Tu proteins cloned and expressed in E. coli. Twenty steers were randomly clustered into four groups (G) of five animals each. Cattle from G1 and G2 were immunized with a mixture of 50 μg of each recombinant protein with Quil A® or Montanide™ adjuvants, respectively. Cattle from G3 and G4 (controls) were immunized with Quil A and Montanide adjuvants, respectively. Cattle received four immunizations at three-week intervals and were challenged with 107 A. marginale-parasitized erythrocytes 42 days after the fourth immunization. After challenge, all cattle showed clinical signs, with a significant drop of packed cell volume and a significant increase of parasitized erythrocytes (p<0.05), requiring treatment with oxytetracycline to prevent death. The levels of IgG2 induced in the immunized groups did not correlate with the observed lack of protection. Additional strategies are required to evaluate the role of these proteins and their potential utility in the development of effective vaccines. EEA Rafaela Fil: Sarli, Macarena. Instituto Nacional de Tecnología Agropecuaria (INTA). Estación Experimental Agropecuaria Rafaela; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Fil: Novoa, María Belen. Instituto Nacional de Tecnología Agropecuaria (INTA). Estación Experimental Agropecuaria Rafaela; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Fil: Mazzucco, Matilde N. Instituto Nacional de Tecnología Agropecuaria (INTA). Estación Experimental Agropecuaria Rafaela; Argentina. Fil: Signorini, Marcelo. Instituto Nacional de Tecnología Agropecuaria (INTA). Estación Experimental Agropecuaria Rafaela; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Fil: Echaide, Ignacio Eduardo. Instituto Nacional de Tecnología Agropecuaria (INTA). Estación Experimental Agropecuaria Rafaela; Argentina. Fil: Echaide, Susana T. de. Instituto Nacional de Tecnología Agropecuaria (INTA). Estación Experimental Agropecuaria Rafaela; Argentina. Fil: Primo, María Evangelina. Instituto Nacional de Tecnología Agropecuaria (INTA). Estación Experimental Agropecuaria Rafaela; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. 2020-03-27T14:02:26Z 2020-03-27T14:02:26Z 2020-02 info:ar-repo/semantics/artículo info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://hdl.handle.net/20.500.12123/6996 https://pubmed.ncbi.nlm.nih.gov/32084216/ 1932-6203 https://doi.org/10.1371/journal.pone.0229301 eng info:eu-repo/semantics/openAccess application/pdf PLOS; National Center for Biotechnology Information PLoS One 15 (2) : e0229301. (2020 Feb 21) |
institution |
INTA AR |
collection |
DSpace |
country |
Argentina |
countrycode |
AR |
component |
Bibliográfico |
access |
En linea |
databasecode |
dig-inta-ar |
tag |
biblioteca |
region |
America del Sur |
libraryname |
Biblioteca Central del INTA Argentina |
language |
eng |
topic |
Anaplasma Marginale Vacuna Proteínas Recombinantes Virulencia Vaccines Recombinant Proteins Virulence Anaplasma Marginale Vacuna Proteínas Recombinantes Virulencia Vaccines Recombinant Proteins Virulence |
spellingShingle |
Anaplasma Marginale Vacuna Proteínas Recombinantes Virulencia Vaccines Recombinant Proteins Virulence Anaplasma Marginale Vacuna Proteínas Recombinantes Virulencia Vaccines Recombinant Proteins Virulence Sarli, Macarena Novoa, María Belen Mazzucco, Matilde N. Signorini, Marcelo Echaide, Ignacio Eduardo Echaide, Susana T. de Primo, María Evangelina A vaccine using Anaplasma marginale subdominant type IV secretion system recombinant proteins was not protective against a virulent challenge |
description |
Anaplasma marginale is the most prevalent tick-borne livestock pathogen with worldwide distribution. Bovine anaplasmosis is a significant threat to cattle industry. Anaplasmosis outbreaks in endemic areas are prevented via vaccination with live A. centrale produced in splenectomized calves. Since A. centrale live vaccine can carry other pathogens and cause disease in adult cattle, research efforts are directed to develop safe recombinant subunit vaccines. Previous work found that the subdominant proteins of A. marginale type IV secretion system (T4SS) and the subdominant elongation factor-Tu (Ef-Tu) were involved in the protective immunity against the experimental challenge in cattle immunized with the A. marginale outer membrane (OM). This study evaluated the immunogenicity and protection conferred by recombinant VirB9.1, VirB9.2, VirB10, VirB11, and Ef-Tu proteins cloned and expressed in E. coli. Twenty steers were randomly clustered into four groups (G) of five animals each. Cattle from G1 and G2 were immunized with a mixture of 50 μg of each recombinant protein with Quil A® or Montanide™ adjuvants, respectively. Cattle from G3 and G4 (controls) were immunized with Quil A and Montanide adjuvants, respectively. Cattle received four immunizations at three-week intervals and were challenged with 107 A. marginale-parasitized erythrocytes 42 days after the fourth immunization. After challenge, all cattle showed clinical signs, with a significant drop of packed cell volume and a significant increase of parasitized erythrocytes (p<0.05), requiring treatment with oxytetracycline to prevent death. The levels of IgG2 induced in the immunized groups did not correlate with the observed lack of protection. Additional strategies are required to evaluate the role of these proteins and their potential utility in the development of effective vaccines. |
format |
info:ar-repo/semantics/artículo |
topic_facet |
Anaplasma Marginale Vacuna Proteínas Recombinantes Virulencia Vaccines Recombinant Proteins Virulence |
author |
Sarli, Macarena Novoa, María Belen Mazzucco, Matilde N. Signorini, Marcelo Echaide, Ignacio Eduardo Echaide, Susana T. de Primo, María Evangelina |
author_facet |
Sarli, Macarena Novoa, María Belen Mazzucco, Matilde N. Signorini, Marcelo Echaide, Ignacio Eduardo Echaide, Susana T. de Primo, María Evangelina |
author_sort |
Sarli, Macarena |
title |
A vaccine using Anaplasma marginale subdominant type IV secretion system recombinant proteins was not protective against a virulent challenge |
title_short |
A vaccine using Anaplasma marginale subdominant type IV secretion system recombinant proteins was not protective against a virulent challenge |
title_full |
A vaccine using Anaplasma marginale subdominant type IV secretion system recombinant proteins was not protective against a virulent challenge |
title_fullStr |
A vaccine using Anaplasma marginale subdominant type IV secretion system recombinant proteins was not protective against a virulent challenge |
title_full_unstemmed |
A vaccine using Anaplasma marginale subdominant type IV secretion system recombinant proteins was not protective against a virulent challenge |
title_sort |
vaccine using anaplasma marginale subdominant type iv secretion system recombinant proteins was not protective against a virulent challenge |
publisher |
PLOS; National Center for Biotechnology Information |
publishDate |
2020-02 |
url |
http://hdl.handle.net/20.500.12123/6996 https://pubmed.ncbi.nlm.nih.gov/32084216/ https://doi.org/10.1371/journal.pone.0229301 |
work_keys_str_mv |
AT sarlimacarena avaccineusinganaplasmamarginalesubdominanttypeivsecretionsystemrecombinantproteinswasnotprotectiveagainstavirulentchallenge AT novoamariabelen avaccineusinganaplasmamarginalesubdominanttypeivsecretionsystemrecombinantproteinswasnotprotectiveagainstavirulentchallenge AT mazzuccomatilden avaccineusinganaplasmamarginalesubdominanttypeivsecretionsystemrecombinantproteinswasnotprotectiveagainstavirulentchallenge AT signorinimarcelo avaccineusinganaplasmamarginalesubdominanttypeivsecretionsystemrecombinantproteinswasnotprotectiveagainstavirulentchallenge AT echaideignacioeduardo avaccineusinganaplasmamarginalesubdominanttypeivsecretionsystemrecombinantproteinswasnotprotectiveagainstavirulentchallenge AT echaidesusanatde avaccineusinganaplasmamarginalesubdominanttypeivsecretionsystemrecombinantproteinswasnotprotectiveagainstavirulentchallenge AT primomariaevangelina avaccineusinganaplasmamarginalesubdominanttypeivsecretionsystemrecombinantproteinswasnotprotectiveagainstavirulentchallenge AT sarlimacarena vaccineusinganaplasmamarginalesubdominanttypeivsecretionsystemrecombinantproteinswasnotprotectiveagainstavirulentchallenge AT novoamariabelen vaccineusinganaplasmamarginalesubdominanttypeivsecretionsystemrecombinantproteinswasnotprotectiveagainstavirulentchallenge AT mazzuccomatilden vaccineusinganaplasmamarginalesubdominanttypeivsecretionsystemrecombinantproteinswasnotprotectiveagainstavirulentchallenge AT signorinimarcelo vaccineusinganaplasmamarginalesubdominanttypeivsecretionsystemrecombinantproteinswasnotprotectiveagainstavirulentchallenge AT echaideignacioeduardo vaccineusinganaplasmamarginalesubdominanttypeivsecretionsystemrecombinantproteinswasnotprotectiveagainstavirulentchallenge AT echaidesusanatde vaccineusinganaplasmamarginalesubdominanttypeivsecretionsystemrecombinantproteinswasnotprotectiveagainstavirulentchallenge AT primomariaevangelina vaccineusinganaplasmamarginalesubdominanttypeivsecretionsystemrecombinantproteinswasnotprotectiveagainstavirulentchallenge |
_version_ |
1756007721272868865 |